UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Tumid lupus erythematosus

Author
Alisa N Femia, MD
Section Editor
Jeffrey Callen, MD, FACP, FAAD
Deputy Editor
Abena O Ofori, MD

INTRODUCTION

Tumid lupus erythematosus (TLE), also known as lupus erythematosus tumidus, is a highly photosensitive form of cutaneous lupus erythematosus (cutaneous LE) that classically presents with erythematous, edematous plaques (picture 1A-C). Traditionally, TLE has been classified as a subset of chronic cutaneous LE. However, the classification of TLE is controversial.

TLE is generally a skin-limited disorder that responds well to photoprotection plus topical treatment or oral antimalarial therapy. Unlike other subtypes of cutaneous LE, associated systemic lupus erythematosus (SLE) is rare.

The clinical features, diagnosis, and management of TLE will be reviewed here. Other manifestations of cutaneous LE are reviewed separately. (See "Overview of cutaneous lupus erythematosus".)

EPIDEMIOLOGY

TLE is an uncommon disorder. The exact prevalence and incidence are unknown.

Unlike systemic lupus erythematosus, which exhibits a strong female predominance, TLE affects women and men nearly equally [1,2]. Some studies have found a slight male predominance [1]. The age-of-onset for TLE varies widely but is often around 30 to 40 years of age [1,3]. TLE in infancy and childhood is rare [4,5]. Most reports of TLE involve Caucasians; however, the distribution of TLE amongst different racial and ethnic populations is not known.

                        

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Feb 2017. | This topic last updated: Tue Dec 13 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
References
Top
  1. Kuhn A, Richter-Hintz D, Oslislo C, et al. Lupus erythematosus tumidus--a neglected subset of cutaneous Lupus erythematosus: report of 40 cases. Arch Dermatol 2000; 136:1033.
  2. Vieira V, Del Pozo J, Yebra-Pimentel MT, et al. Lupus erythematosus tumidus: a series of 26 cases. Int J Dermatol 2006; 45:512.
  3. Schmitt V, Meuth AM, Amler S, et al. Lupus erythematosus tumidus is a separate subtype of cutaneous lupus erythematosus. Br J Dermatol 2010; 162:64.
  4. Kuhn A, Schuppe HC, Megahed M, et al. Kutaner lupus erythematodes im Kindesalter (Tumidus-Typ). Z Hautkr 1997; 72:299.
  5. Sonntag M, Lehmann P, Megahed M, et al. Lupus erythematosus tumidus in childhood. Report of 3 patients. Dermatology 2003; 207:188.
  6. Yu C, Chang C, Zhang J. Immunologic and genetic considerations of cutaneous lupus erythematosus: a comprehensive review. J Autoimmun 2013; 41:34.
  7. Kind P, Lehmann P, Plewig G. Phototesting in lupus erythematosus. J Invest Dermatol 1993; 100:53S.
  8. Kuhn A, Wozniacka A, Szepietowski JC, et al. Photoprovocation in cutaneous lupus erythematosus: a multicenter study evaluating a standardized protocol. J Invest Dermatol 2011; 131:1622.
  9. Kuhn A, Sonntag M, Richter-Hintz D, et al. Phototesting in lupus erythematosus tumidus--review of 60 patients. Photochem Photobiol 2001; 73:532.
  10. Gambichler T, Pätzholz J, Schmitz L, et al. FOXP3+ and CD39+ regulatory T cells in subtypes of cutaneous lupus erythematosus. J Eur Acad Dermatol Venereol 2015; 29:1972.
  11. Böckle BC, Sepp NT. Smoking is highly associated with discoid lupus erythematosus and lupus erythematosus tumidus: analysis of 405 patients. Lupus 2015; 24:669.
  12. Schneider SW, Staender S, Schlüter B, et al. Infliximab-induced lupus erythematosus tumidus in a patient with rheumatoid arthritis. Arch Dermatol 2006; 142:115.
  13. Sohl S, Renner R, Winter U, et al. [Drug-induced lupus erythematosus tumidus during treatment with adalimumab]. Hautarzt 2009; 60:826.
  14. Chogle AR, Shah CV, Murthy AK. Role of anti-tumor necrosis factor-alpha blockers in inducing lupus erythematosus tumidus in "rhupus syndrome". J Rheumatol 2011; 38:1218.
  15. Brown CW Jr, Deng JS. Thiazide diuretics induce cutaneous lupus-like adverse reaction. J Toxicol Clin Toxicol 1995; 33:729.
  16. Kuhn A, Bein D, Bonsmann G. The 100th anniversary of lupus erythematosus tumidus. Autoimmun Rev 2009; 8:441.
  17. Schepis C, Lentini M, Siragusa M, Batolo D. ACE-inhibitor-induced drug eruption resembling lymphocytic infiltration (of Jessner-Kanof) and Lupus erythematosus tumidus. Dermatology 2004; 208:354.
  18. Aguayo-Leiva I, Vano-Galvan S, Carrillo-Gijon R, Jaén-Olasolo P. Lupus tumidus induced by bortezomib not requiring discontinuation of the drug. J Eur Acad Dermatol Venereol 2010; 24:1363.
  19. Böckle BC, Baltaci M, Weyrer W, Sepp NT. Bortezomib-induced lupus erythematosus tumidus. Oncologist 2009; 14:637.
  20. Guarneri C, Lentini M, Polimeni G, et al. Ustekinumab-induced drug eruption resembling lymphocytic infiltration (of Jessner-Kanof) and lupus erythematosus tumidus. Br J Clin Pharmacol 2016; 81:792.
  21. Zandman-Goddard G, Solomon M, Barzilai A, Shoenfeld Y. Lupus erythematosus tumidus induced by sex reassignment surgery. J Rheumatol 2007; 34:1938.
  22. Kuhn A, Ruzicka T. Classification of cutaneous lupus erythematosus. In: Cutaneous Lupus Erythematosus, 1st ed, Kuhn A, Lehmann P, Ruzicka T (Eds), Springer Verlag, Berlin 2005. p.53.
  23. Mutasim DF. Lupus erythematosus tumidus as a separate subtype of cutaneous lupus erythematosus. Br J Dermatol 2010; 163:230; author reply 231.
  24. Callen JP. Clinically relevant information about cutaneous lupus erythematosus. Arch Dermatol 2009; 145:316.
  25. Maize JC Jr, Costner M. Tumid lupus erythematosus: a form of lupus erythematosus. Arch Dermatol 2010; 146:451; author reply 450.
  26. Stead J, Headley C, Ioffreda M, et al. Coexistence of tumid lupus erythematosus with systemic lupus erythematosus and discoid lupus erythematosus: a report of two cases of tumid lupus. J Clin Rheumatol 2008; 14:338.
  27. Pacheco TR, Spates ST, Lee LA. Unilateral tumid lupus erythematosus. Lupus 2002; 11:388.
  28. Hinz T, Hornung T, Wenzel J, Bieber T. Lupus tumidus following the lines of Blaschko. Int J Dermatol 2013; 52:1615.
  29. Werth VP, White WL, Sanchez MR, Franks AG. Incidence of alopecia areata in lupus erythematosus. Arch Dermatol 1992; 128:368.
  30. Vassallo C, Colombo G, Canevari R, et al. Monolateral severe eyelid erythema and edema as unique manifestation of lupus tumidus. Int J Dermatol 2005; 44:858.
  31. Alexiades-Armenakas MR, Baldassano M, Bince B, et al. Tumid lupus erythematosus: criteria for classification with immunohistochemical analysis. Arthritis Rheum 2003; 49:494.
  32. Rodriguez-Caruncho C, Bielsa I, Fernández-Figueras MT, et al. Lupus erythematosus tumidus: a clinical and histological study of 25 cases. Lupus 2015; 24:751.
  33. Cozzani E, Christana K, Rongioletti F, et al. Lupus erythematosus tumidus: clinical, histopathological and serological aspects and therapy response of 21 patients. Eur J Dermatol 2010; 20:797.
  34. Bonciani D, Antiga E, Bonciolini V, et al. Homocysteine serum levels are increased and correlate with disease severity in patients with lupus erythematosus. Clin Exp Rheumatol 2016; 34:76.
  35. Rémy-Leroux V, Léonard F, Lambert D, et al. Comparison of histopathologic-clinical characteristics of Jessner's lymphocytic infiltration of the skin and lupus erythematosus tumidus: Multicenter study of 46 cases. J Am Acad Dermatol 2008; 58:217.
  36. Choonhakarn C, Poonsriaram A, Chaivoramukul J. Lupus erythematosus tumidus. Int J Dermatol 2004; 43:815.
  37. Kuhn A, Sonntag M, Ruzicka T, et al. Histopathologic findings in lupus erythematosus tumidus: review of 80 patients. J Am Acad Dermatol 2003; 48:901.
  38. Lipsker D, Mitschler A, Grosshans E, Cribier B. Could Jessner's lymphocytic infiltrate of the skin be a dermal variant of lupus erythematosus? An analysis of 210 cases. Dermatology 2006; 213:15.
  39. Cohen PR, Rabinowitz AD, Ruszkowski AM, DeLeo VA. Reticular erythematous mucinosis syndrome: review of the world literature and report of the syndrome in a prepubertal child. Pediatr Dermatol 1990; 7:1.
  40. Braddock SW, Kay HD, Maennle D, et al. Clinical and immunologic studies in reticular erythematous mucinosis and Jessner's lymphocytic infiltrate of skin. J Am Acad Dermatol 1993; 28:691.
  41. Cinotti E, Merlo V, Kempf W, et al. Reticular erythematous mucinosis: histopathological and immunohistochemical features of 25 patients compared with 25 cases of lupus erythematosus tumidus. J Eur Acad Dermatol Venereol 2015; 29:689.
  42. Kuhn A, Gensch K, Haust M, et al. Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: a randomized, vehicle-controlled, double-blind study. J Am Acad Dermatol 2011; 64:37.
  43. Boeckler P, Cosnes A, Francès C, et al. Association of cigarette smoking but not alcohol consumption with cutaneous lupus erythematosus. Arch Dermatol 2009; 145:1012.
  44. Chasset F, Francès C, Barete S, et al. Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature. J Am Acad Dermatol 2015; 72:634.
  45. Kuhn A, Gensch K, Haust M, et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial. J Am Acad Dermatol 2011; 65:54.
  46. Kreuter A, Gambichler T, Breuckmann F, et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol 2004; 51:407.
  47. Marmor MF, Kellner U, Lai TY, et al. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology 2016; 123:1386.
  48. Chang J, Werth VP. Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects. Expert Rev Clin Immunol 2016; 12:1109.
  49. Chasset F, Arnaud L, Costedoat-Chalumeau N, et al. The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study. J Am Acad Dermatol 2016; 74:693.
  50. Chang AY, Piette EW, Foering KP, et al. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. Arch Dermatol 2011; 147:1261.
  51. Kreuter A, Gaifullina R, Tigges C, et al. Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking. Arch Dermatol 2009; 145:244.
  52. Wenzel J, Brähler S, Bauer R, et al. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol 2005; 153:157.
  53. Hanjani NM, Nousari CH. Mycophenolate mofetil for the treatment of cutaneous lupus erythematosus with smoldering systemic involvement. Arch Dermatol 2002; 138:1616.
  54. Gammon B, Hansen C, Costner MI. Efficacy of mycophenolate mofetil in antimalarial-resistant cutaneous lupus erythematosus. J Am Acad Dermatol 2011; 65:717.
  55. Braunstein I, Goodman NG, Rosenbach M, et al. Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare. J Am Acad Dermatol 2012; 66:571.
  56. Cortés-Hernández J, Ávila G, Vilardell-Tarrés M, Ordi-Ros J. Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus. Arthritis Res Ther 2012; 14:R265.
  57. Cortés-Hernández J, Torres-Salido M, Castro-Marrero J, et al. Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome. Br J Dermatol 2012; 166:616.